Patents by Inventor Richard T. Surosky

Richard T. Surosky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for producing recombinant AAV
    Patent number: 11718834
    Abstract: Provided herein are nucleic acid constructs, host insect cells, and methods for producing recombinant AAV capsids with high potency at high yield.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: August 8, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Andrea J. Kang, Richard T. Surosky, Alex Michael Ward
  • NOVEL COMPOSITIONS AND METHODS FOR PRODUCING RECOMBINANT AAV
    Publication number: 20230020565
    Abstract: Provided herein are nucleic acid constructs, host insect cells, and methods for producing recombinant AAV capsids with high potency at high yield.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 19, 2023
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Alex Michael Ward, Hung Tran, Andrea J. Kang, Tzu-Hung Chen, Richard T. Surosky
  • AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFOR
    Publication number: 20220016264
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: June 23, 2021
    Publication date: January 20, 2022
    Inventors: Alejandra E. ARBETMAN, Peter C. COLOSI, Michael A. LOCHRIE, Richard T. SUROSKY
  • AAV virions with decreased immunoreactivity and uses therefor
    Patent number: 11083800
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: August 10, 2021
    Assignee: Genzyme Corporation
    Inventors: Alejandra E. Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • COMPOSITIONS AND METHODS FOR PRODUCING RECOMBINANT AAV
    Publication number: 20200283739
    Abstract: Provided herein are nucleic acid constructs, host insect cells, and methods for producing recombinant AAV capsids with high potency at high yield.
    Type: Application
    Filed: February 14, 2020
    Publication date: September 10, 2020
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Andrea J. Kang, Richard T. Surosky, Alex Michael Ward
  • AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFOR
    Publication number: 20190314526
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: January 29, 2019
    Publication date: October 17, 2019
    Inventors: Alejandra E. ARBETMAN, Peter C. COLOSI, Michael A. LOCHRIE, Richard T. SUROSKY
  • AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFOR
    Publication number: 20180280540
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: December 7, 2017
    Publication date: October 4, 2018
    Applicant: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFOR
    Publication number: 20170232117
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Application
    Filed: October 18, 2016
    Publication date: August 17, 2017
    Applicant: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • AAV virions with decreased immunoreactivity and uses therefor
    Patent number: 9506083
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: November 29, 2016
    Assignee: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • AAV virions with decreased immunoreactivity and uses therefor
    Patent number: 7259151
    Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: August 21, 2007
    Assignee: Genzyme Corporation
    Inventors: Alejandra Elena Arbetman, Peter C. Colosi, Michael A. Lochrie, Richard T. Surosky
  • Targeted nucleotide sequence delivery and integration system
    Patent number: 6207457
    Abstract: A novel targeted nucleotide sequence delivery and integration system is provided. The integration system employs nucleic acid constructs having a targeting sequence capable of binding AAV Rep and a heterologous nucleotide sequence arranged relative to the targeting sequence such that the targeting sequence is capable of directing the integration of the heterologous sequence into a target site in a recipient genome. The system further employs Rep expression products which provide integration functions effective to mediate the site-specific integration of the targeting sequence and the heterologous sequence into the recipient genome. Methods are described, whereby the nucleotide sequence integration system can deliver and efficiently integrate large nucleotide sequences into target sites in recipient cell genomes. Therapeutic methods are also provided, wherein the integration systems are used to insert various therapeutically relevant nucleotide sequences into selected cells from a subject.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: March 27, 2001
    Assignee: Avigen, Inc.
    Inventors: Georges Natsoulis, Richard T. Surosky